A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
← catalyst calendarNCT05774951 · readout in 244 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
4,300estimated
Sites
709
Countries
Argentina, Australia, Austria +36
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-31 | actual | When the study began enrolling |
| Primary completion | 2027-04-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2036-05-29 | estimated | The whole study's end, after follow-up |
| First posted | 2023-03-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer, Early Breast Cancer
Interventions
- Drug: Camizestrant — also filed as AZD9833
- Drug: Tamoxifen
- Drug: Anastrozole
- Drug: Letrozole
- Drug: Exemestane
Primary outcome
what the primary-completion date above is the date OFInvasive breast cancer-free survival (IBCFS)
measured Up to 10 years
Publications
- PMID 40017004 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed